Truist Initiates MBX Biosciences Coverage with $50 Price Target
Truist analyst sets Buy rating on MBX Biosciences with $50 target, citing strong potential for lead drug canvuparatide (MBX 2109) with projected $3.2B peak sales by 2036.
/ 1680 items
#XY↓
Halozyme Gets Upgrade as Medicare Impact Fears Ease
Leerink upgrades Halozyme to Market Perform after company reveals only 20% of ENHANZE sales come from Medicare Part B, significantly less than feared. Price target remains $70.
Shah Capital Urges Novavax Sale After COVID Vaccine Struggles Continue
Novavax's second-largest shareholder Shah Capital pushes for company sale, citing poor COVID vaccine sales and untapped potential worth $5 billion under larger pharma ownership.
Senti Biosciences Gets Bullish Analyst Coverage with 614% Upside Potential
H.C. Wainwright initiates Senti Bio with Buy rating and $12 target. Cancer therapy developer's CAR-NK platform shows promise for blood cancers and solid tumors.
BioCryst to Acquire Astria Therapeutics in $700M Deal to Boost Rare Disease Portfolio
BioCryst Pharmaceuticals announces $700M acquisition of Astria Therapeutics, adding promising hereditary angioedema drug to expand rare disease treatment options.
Johnson & Johnson Spins Off DePuy Synthes Amid Pricing Pressure and Strategic Focus on High-Growth Markets
J&J is spinning off its slower-growing $9.2B DePuy Synthes joint replacement business to focus on high-profit drugs and handle US price demands.